All In Biotech

Drug Trial Radar · NCT07567833

Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 31, 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Jaeb Center for Health ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Eye Institute (NEI)
First posted
May 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A considerable hurdle to the development of novel, more effective therapies for diabetic retinal disease is the limited number of primary endpoints available for use in regulatory trials. Current endpoints necessitate long trial durations and a greater number of participants to show efficacy. Thus, a better understanding of the structural and functional changes in the retina occurring in people with diabetes is essential for developing primary endpoints and validating surrogate and clinical endpoints.

Conditions

  • Diabetic Retinal Disease

Interventions

  • Anti-Vascular Endothelial Growth FactorDrug

    All study eyes will receive an injection of anti-VEGF at baseline, 4, and 8 weeks. The participant will then be assessed for treatment every 8 weeks. At and after the 16-week visit, an injection will only be given if the eye has center-involved DME or visual acuity worse than 20/20 (presumed to be due to DME). Otherwise, an injection will not be given. The follow-up interval remains 8 weeks regardless of whether an injection is given or deferred. However, if an injection is deferred and the participant experiences vision issues or other symptoms, they may return for evaluation prior to 8 weeks (e.g., in 4 weeks) and can receive an injection (provided it has been at least 21 days since the last injection).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in multifocal pupillographic objective perimetry (mfPOP) response delaysTime frame: Baseline to 1 year
  2. Change in area under the log contrast sensitivity function (AULCSF)Time frame: Baseline to 1 year
  3. Change in electroretinography parameterTime frame: Baseline to 1 year
  4. Change in reading performanceTime frame: Baseline to 1 year
  5. Change in visual field functionTime frame: Baseline to 1 year
  6. Change in diabetic retinopathy severityTime frame: Baseline to 1 year
  7. Change in retinal vascular pathologyTime frame: Baseline to 1 year
  8. Change in retinal structureTime frame: Baseline to 1 year
  9. Change in retinal microvascular parameterTime frame: Baseline to 1 year

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Retina Consultants of Southern California

    Huntington Beach, California · Recruiting

  • Southeast Retina Center, P.C.

    Augusta, Georgia · Recruiting

  • Boston Medical Center Corporation

    Boston, Massachusetts · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Retina-Vitreous Consultants, Inc.

    Monroeville, Pennsylvania · Recruiting

  • Pittsburgh Clinical Trial Consortium

    Sewickley, Pennsylvania · Recruiting

  • Retina Consultants of Texas

    Beaumont, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.